Immunic presents data from phase 2 emphasis trial of vidofludimus calcium in relapsing-remitting multiple sclerosis at actrims forum 2023

– long-term open-label treatment with vidofludimus calcium was associated with a low rate of confirmed disability worsening (cdw) over time – – cdw data compares favorably to historical trial data for currently available multiple sclerosis treatments – new york , feb. 22, 2023 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today announced that robert j. fox, m.d., staff neurologist, mellen center for multiple sclerosis, vice-chair for research, neurologic institute, cleveland clinic, cleveland, ohio, will present data from the blinded and open-label extension (ole) parts of the company's phase 2 emphasis trial of lead asset, vidofludimus calcium (imu-838), a selective oral dhodh inhibitor, in relapsing-remitting multiple sclerosis (rrms) at the eighth annual americas committee for treatment and research in multiple sclerosis (actrims) forum 2023, taking place february 23-25 in san diego, california.
IMUX Ratings Summary
IMUX Quant Ranking